Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Jan;43(1):163-5.
doi: 10.1128/AAC.43.1.163.

Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects

G W Amsden  1 , A N Nafziger, G Foulds
Affiliations
Clinical Trial

Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects

G W Amsden et al. Antimicrob Agents Chemother. 1999 Jan.

Abstract

The pharmacokinetics in serum and leukocyte (WBC) exposures of 1,500 mg of oral azithromycin administered as 3-day (500 mg/day, days 1 to 3) and 5-day (500 mg on day 1 and 250 mg/day on days 2 to 5) regimens were compared in 12 healthy volunteers. Serum, polymorphonuclear leukocytes, and mononuclear leukocytes were collected over a 12-day period from the start of each regimen. Results of the study indicate that the exposures of serum and both types of WBCs were similar with both regimens. Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens. Terminal half-lives in serum obtained by both regimens were essentially equal at 66 h and consistent with past reports. These results indicate that the standard 1,500-mg dose of oral azithromycin can be administered over either 5 or 3 days.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Mean azithromycin concentrations in serum versus time for the 3- and 5-day regimens.
See this image and copyright information in PMC

References

    1. Amsden G W. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996;18:56–72. - PubMed
    1. Amsden G W, Ballow C H, Forrest A. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin Drug Invest. 1997;13:152–161.
    1. Baldwin D R, Wise R, Andrews J M, Ashby J P, Honeybourne D. Azithromycin concentrations at the site of pulmonary infections. Eur Respir J. 1990;3:886–890. - PubMed
    1. Ballow C H, Amsden G W. Azithromycin: the first azalide antibiotic. Ann Pharmacother. 1992;26:1253–1261. - PubMed
    1. Ballow C H, Amsden G W, Highet V S, Forrest A. Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leukocytes and inflammatory vs. non-inflammatory skin blisters. Clin Drug Invest. 1998;15:159–167. - PubMed

Publication types